KCNN4 and non-small cell lung carcinoma: Here we tested whether the efficacy of the EGFR-TKI erlotinib can be enhanced and resistance of NSCLC cells to this drug be overcome by combining it with the highly specific KCa3.1 inhibitor senicapoc.